Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.

Alba Cervantes GonzálezDavid J IrwinDaniel AlcoleaCorey T McMillanAlice Chen-PlotkinDavid WolkSònia SirisiOriol Dols-IcardoMarta Querol-VilasecaIgnacio Illán-GalaMiguel Angel Santos-SantosJuan ForteaEdward B LeeJohn Q TrojanowskiMurray GrossmanAlberto LleóOlivia Belbin

Published in: Molecular neurodegeneration (2022)

These synaptic panels have potential in the differential diagnosis of FTLD neuropathologic subtypes and as surrogate markers of cognitive performance in future clinical trials targeting TDP-43 or tau.

Keyphrases

cerebrospinal fluid
amyotrophic lateral sclerosis
clinical trial
prefrontal cortex
current status
cancer therapy
protein protein
randomized controlled trial
binding protein
amino acid
phase ii
drug delivery
risk assessment